By Michele Maatouk
Date: Wednesday 11 Dec 2019
(Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.
In a brief statement, the company noted the volatility in its share price following the recently-announced licensing and development agreement with US speciality pharmaceutical group Avion - which will see Avion will fund an international phase III trial for its lead programme, Lupuzor - and speculation about a possible fundraising.
"The board can confirm that the company is adequately funded and has no intention of raising funds," it said.
At 1510 GMT, the shares were up 1.5% at 18.02p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news